Table 3.

Susceptibility (μg/ml) of clinical isolates ofS. pneumoniae, Haemophilus spp., and P. aeruginosa

Species and agentMIC (μg/ml) of NCTC control strainMIC (μg/ml)a
50%90%Range
S. pneumoniae(n = 19)
 Ciprofloxacin0.51322–32
 Ciprofloxacin + reserpine0.50.580.5–8
 Sparfloxacin0.250.5160.03–32
 Clinafloxacin0.060.1210.06–1
 Gatifloxacin0.50.2540.03–8
 Grepafloxacin0.50.5160.06–64
 Levofloxacin0.51320.06–32
 Moxifloxacin0.50.2540.06–4
 Trovafloxacin0.250.1240.06–4
Haemophilus spp. (n = 5)
 Ciprofloxacin0.0080.5–8
 Sparfloxacin0.0080.5–8
 Clinafloxacin0.0040.12–1
 Gatifloxacin0.060.25–2
 Grepafloxacin0.121–8
 Levofloxacin0.061–16
 Moxifloxacin0.061–4
 Trovafloxacin0.060.25–1
P. aeruginosa (n = 10)
 Ciprofloxacin1280.25–8
 Sparfloxacin48328–32
 Clinafloxacin1140.06–4
 Gatifloxacin44160.5–16
 Grepafloxacin88320.5–32
 Levofloxacin14160.5–16
 Moxifloxacin16163216–32
 Trovafloxacin0.54320.5–32
  • a 50% and 90%, MICs at which 50 and 90% of the isolates are inhibited, respectively.